Skip to main content
Retour
TRDA logo

Entrada Therapeutics, Inc.

Qualité des données : 100%
TRDA
NASDAQ Healthcare Biotechnology
CEO: Dipal Doshi Employees: 183 IPO: Oct 29, 2021
Prix
13,48 €
Variation
▲ 0,86 €
6,81%
Cap. Boursière
516,07M
Fourchette du Jour
12,58 € 13,66 €
Fourchette 52 Semaines
4,93 € 13,66 €
Volume
257 064
Moyenne 50J / 200J
11,74 €
8,49 €
Clôture Précédente
12,62 €

Quick Summary

Points Clés

Earnings declined -319,04% over the past year
Debt/Equity of 0,17 — conservative balance sheet
Negative free cash flow of -129,55M
PEG of 0,01 suggests growth is underpriced
Capital efficient — spends only 4,10% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-87,94%
Earnings (1Y)-319,04%
FCF Growth (3Y)N/A

Qualité

Return on Equity
-39,13%
En dessous de la moyenne du secteur (3,61%)
ROIC-32,77%
Net Margin-565,48%
Op. Margin-613,66%

Sécurité

Debt / Equity
0,17
En dessous de la moyenne du secteur (0,23)
Current Ratio12,53
Interest Coverage0,00

Valorisation

P/E Ratio
-3,59
En dessous de la moyenne du secteur (0,23)
Forward P/EN/A
P/B Ratio1,69
EV/EBITDAN/A
Dividend Yield0,00%

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (638 pairs)

Métrique Action Médiane du Secteur
P/E -3,6 0,2
P/B 1,7 2,9
ROE % -39,1 3,6
Net Margin % -565,5 3,9
Rev Growth 5Y % 9,6
D/E 0,2 0,2

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

All Fundamental Metrics

Growth
Revenue Growth (1Y) -87,94% Revenue Growth (3Y) -55,61%
Earnings Growth (1Y) -319,04% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 25,42M Net Income (TTM) -143,75M
ROE -39,13% ROA -38,09%
Gross Margin 83,89% Operating Margin -613,66%
Net Margin -565,48% Free Cash Flow (TTM) -129,55M
ROIC -32,77% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,17 Current Ratio 12,53
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,59 Forward P/E N/A
P/B Ratio 1,69 P/S Ratio 20,30
PEG Ratio 0,01 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -25,10%
Market Cap 516,07M Enterprise Value 476,61M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 25,42M 210,78M 129,01M 0,0 0,0
Net Income -143,75M 65,63M -6,69M -94,62M -51,16M
EPS (Diluted) -3,47 1,68 -0,20 -2,79 -1,60
Gross Profit 21,33M 210,78M 129,01M 0,0 0,0
Operating Income -156,00M 47,01M -3,16M -97,25M -51,13M
EBITDA -142,40M 50,78M -321 000,0 -95,35M -50,01M
R&D Expenses 142,27M 125,31M 99,88M 66,61M 35,93M
SG&A Expenses 41,05M 38,47M 32,29M 30,64M 15,20M
D&A 425 000,0 3,77M 2,84M 1,90M 1,12M
Interest Expense 0,0 0,0 0,0 2,63M 0,0
Income Tax 924 000,0 859 000,0 18,74M 0,0 0,0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 377,38M 526,32M 469,19M 252,06M 305,83M
Total Liabilities 71,25M 97,64M 226,83M 39,50M 7,12M
Shareholders' Equity 306,13M 428,68M 242,36M 212,55M 298,72M
Total Debt 50,93M 59,21M 68,23M 25,94M 0,0
Cash & Equivalents 90,39M 101,21M 67,60M 45,16M 291,06M
Current Assets 306,25M 440,04M 369,77M 209,88M 298,70M
Current Liabilities 24,45M 39,48M 158,80M 21,97M 6,72M